Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Cutlip, S. Windecker, R. Mehran, A. Boam, D. Cohen, G. Es, P. Steg, M. Morel, L. Mauri, P. Vranckx, E. Mcfadden, A. Lansky, M. Hamon, M. Krucoff, P. Serruys (2007)
Clinical End Points in Coronary Stent Trials: A Case for Standardized DefinitionsCirculation, 115
V. Farooq, S. Head, A. Kappetein, P. Serruys (2013)
Widening clinical applications of the SYNTAX ScoreHeart, 100
E. Christiansen, L. Jensen, P. Thayssen, H. Tilsted, L. Krusell, K. Hansen, A. Kaltoft, M. Maeng, S. Kristensen, H. Bøtker, C. Terkelsen, A. Villadsen, J. Ravkilde, J. Aarøe, M. Madsen, L. Thuesen, J. Lassen (2013)
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trialThe Lancet, 381
A. Latib, L. Ferri, A. Ielasi, C. Godino, A. Chieffo, V. Magni, G. Bassanelli, Andrew Sharp, R. Gerber, I. Michev, M. Carlino, F. Airoldi, G. Sangiorgi, M. Montorfano, A. Colombo (2009)
Clinical outcomes after unrestricted implantation of everolimus-eluting stents.JACC. Cardiovascular interventions, 2 12
Soojin Lee, K. Baek, K. Chun (2014)
Cost-Effectiveness of Drug-Eluting vs. Bare-Metal Stents in Patients with Coronary Artery Disease from the Korean National Health Insurance DatabaseYonsei Medical Journal, 55
G. Danzi, B. Chevalier, P. Urban, F. Fath-ordoubadi, D. Carrié, M. Wiemer, A. Serra, W. Wijns, P. Kala, A. Stabile, J. Ruigómez, D. Sagic, Peep Laanmets, G. Strupp, N. West, D. Paunovic (2012)
Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 8 1
C. Godino, D. Parenti, D. Regazzoli, D. Rutigliano, L. Lucisano, G. Viani, M. Spartera, A. Chieffo, M. Donahue, A. Cappelletti, N. Locuratolo, R. Parisi, R. Fattori, P. Presbitero, A. Margonato, C. Briguori, G. Sardella, A. Colombo (2014)
One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: the Italian Nobori Stent Prospective Registry.International journal of cardiology, 177 1
Masahiro Natsuaki, K. Kozuma, T. Morimoto, K. Kadota, T. Muramatsu, Y. Nakagawa, T. Akasaka, K. Igarashi, K. Tanabe, Y. Morino, T. Ishikawa, H. Nishikawa, M. Awata, M. Abe, H. Okada, Y. Takatsu, Nobuhiko Ogata, Kazuo Kimura, K. Urasawa, Y. Tarutani, N. Shiode, Takeshi Kimura (2013)
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial.Journal of the American College of Cardiology, 62 3
G. Levine, E. Bates, J. Blankenship, S. Bailey, J. Bittl, B. Cercek, C. Chambers, S. Ellis, R. Guyton, S. Hollenberg, U. Khot, R. Lange, L. Mauri, R. Mehran, I. Moussa, D. Mukherjee, B. Nallamothu, H. Ting (2011)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Journal of the American College of Cardiology, 58 24
C. Stettler, Simon Wandel, S. Allemann, A. Kastrati, M. Morice, A. Schömig, M. Pfisterer, G. Stone, M. Leon, J. Lezo, J. Goy, Seung‐Jung Park, M. Sabaté, M. Suttorp, H. Kelbaek, C. Spaulding, M. Menichelli, P. Vermeersch, M. Dirksen, P. Červinka, A. Petronio, A. Nordmann, P. Diem, B. Meier, M. Zwahlen, S. Reichenbach, S. Trelle, S. Windecker, P. Jüni (2007)
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisThe Lancet, 370
B. Chevalier, W. Wijns, S. Silber, Eulogio García, A. Serra, D. Paunovic, P. Serruys (2015)
Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 11 5
G. Stone, J. Moses, S. Ellis, J. Schofer, K. Dawkins, M. Morice, A. Colombo, E. Schampaert, E. Grube, A. Kirtane, D. Cutlip, M. Fahy, S. Pocock, R. Mehran, M. Leon (2007)
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.The New England journal of medicine, 356 10
G. Stefanini, B. Kalesan, P. Serruys, D. Heg, P. Buszman, A. Linke, T. Ischinger, V. Klauss, F. Eberli, W. Wijns, M. Morice, C. Mario, R. Corti, D. Antoni, H. Sohn, P. Eerdmans, G. Es, B. Meier, S. Windecker, P. Jüni (2011)
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trialThe Lancet, 378
P. Smits, S. Hofma, M. Togni, N. Vázquez, M. Valdés, V. Voudris, T. Slagboom, Jean-Jaques Goy, A. Vuillomenet, A. Serra, R. Nouche, P. Heijer, M. Ent (2013)
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trialThe Lancet, 381
S. Garg, C. Bourantas, P. Serruys (2013)
New concepts in the design of drug-eluting coronary stentsNature Reviews Cardiology, 10
Objectives To investigate the long‐term clinical outcomes of biolimus‐eluting stents with biodegradable polymers in real‐world clinical practice. Background Long‐term clinical outcomes of biolimus‐eluting stents have not been clearly established. Methods A total of 824 all‐comer patients (971 lesions) treated with unrestricted implantation of a biolimus‐eluting stent with a biodegradable polymer were prospectively enrolled. Patients were divided into complex (413 patients) versus noncomplex (411 patients) groups according to the complexity of coronary lesions. Long‐term clinical outcomes for stent efficacy (target lesion revascularization) and safety (composite of cardiac death, target lesion‐related myocardial infarction, and definite or probable stent thrombosis) were compared between the two groups during 5 years of follow‐up. Results The complex group showed higher rates of decreased left ventricular ejection fraction, impaired renal function, previous history of myocardial infarction, and diabetes mellitus compared to the noncomplex group. In the overall population, the 5‐year cumulative rate of target lesion revascularization was 4.8% (8.3% in the complex group vs 1.6% in the noncomplex group, P < 0.001). For stent safety, the 5‐year cumulative rate for a composite of cardiac death, target lesion‐related myocardial infarction, and stent thrombosis was 2.5% overall (3.9% in the complex group vs 1.1% in the noncomplex group, P = 0.010). Overall 5‐year cumulative rate of stent thrombosis was 0.4% (0.5% in the complex vs 0.2% in the noncomplex group, P = 0.561) with no very late stent thrombosis (VLST). Conclusions Biodegradable polymer‐based biolimus‐eluting stents showed favorable efficacy and safety in all‐comer patients during 5 years of follow‐up. (J Interven Cardiol 2016;29:162–167)
Journal of Interventional Cardiology – Wiley
Published: Apr 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.